Lymphoma Trial, Recruiting NCT06002828 Sponsor: ECOG-ACRIN Cancer Research Group Condition: Lymphoma
Back to Lymphoma

Lymphoma Trial, Recruiting

NCT06002828
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older at the time of joining the trial
  • People who were between the ages of 15 and 39 when they were first diagnosed with Hodgkin lymphoma or non-Hodgkin lymphoma (two types of blood cancer)
  • People whose cancer treatment has been completed and whose doctor has confirmed their cancer is in full remission (complete response)
  • People whose last cancer treatment finished within one year before joining the trial — this includes any type of anti-cancer treatment such as chemotherapy, targeted drug therapy (by IV or tablet), or radiation, whether given as part of a clinical trial or standard care
  • People with a general health and activity level that falls within a certain range, as assessed by a standard medical scoring system (confirm with trial site for details on what scores are accepted)
  • People who speak English, as the quality-of-life forms used in this study are only available in English and cannot be translated
  • People who are not currently receiving active treatment for their lymphoma
  • People who have access to the internet through a computer, tablet, or smartphone
  • People who have an email address
  • People who are able to understand and agree to sign a consent form — those who have difficulty making decisions on their own may still be considered eligible if a legally authorised representative, caregiver, or family member is available to assist

Who may not be able to join:

  • People who are currently still receiving active treatment for Hodgkin lymphoma or non-Hodgkin lymphoma
  • People whose last cancer treatment was completed more than one year before the time of joining the trial
  • People who do not speak English (confirm with trial site)
  • People who do not have internet access or an email address

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
ECOG-ACRIN Cancer Research Group
Registry
ClinicalTrials.gov
Start date
13 October 2023
Est. completion
1 February 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Disease free survival (DFS); Overall survival (OS); Comorbidities (including symptoms, late effects)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov